Core Insights - Journey Medical Corporation reported total revenues of $15.0 million for the second quarter of 2025, showing a slight increase from $14.9 million in the same quarter of the previous year [5] - Emrosi™ generated net sales of $2.8 million in its first full quarter on the market, indicating strong initial adoption and prescription ramp [2][5] - The company joined the Russell 2000® and Russell 3000® Indexes in June 2025, reflecting its growth and market presence [2][11] Financial Results - Total net product revenues for the second quarter of 2025 were $15.0 million, compared to $14.9 million in the prior year quarter [5] - Gross margin increased to 67% in Q2 2025 from 61% in Q2 2024, attributed to lower product costs and a favorable sales mix [5] - Selling, general and administrative expenses rose to $11.9 million in Q2 2025, up from $10.3 million in Q2 2024, primarily due to costs associated with the Emrosi launch [5] - The net loss for the second quarter was $3.8 million, or $(0.16) per share, compared to a net loss of $3.4 million, or $(0.17) per share, in the prior year [5][16] - At the end of Q2 2025, the company had $20.3 million in cash and cash equivalents, unchanged from December 31, 2024 [5] Recent Corporate Highlights - In July 2025, Journey Medical expanded payer access for Emrosi to over 100 million commercial lives in the U.S., up from 54 million in May 2025 [4] - The full commercial launch of Emrosi began on April 7, 2025, and has shown strong traction in the market [4] - Emrosi was featured in a segment on "The Balancing Act®" on Lifetime TV, highlighting treatment options for managing rosacea [11]

Core Insights - Journey Medical Corporation reported total net product revenues of $13.1 million for Q1 2025, consistent with $13.0 million in Q1 2024, with $2.1 million attributed to the launch of Emrosi [3][15] - The gross margin improved to 64% in Q1 2025 from 54% in the prior year, driven by lower product costs [3] - The company experienced a net loss of $4.1 million, or $(0.18) per share, for Q1 2025, a significant reduction from a net loss of $10.4 million, or $(0.53) per share, in Q1 2024 [3][21] Financial Performance - Cash and cash equivalents increased to $21.1 million as of March 31, 2025, compared to $20.3 million at the end of 2024 [3] - Research and development costs were nil in Q1 2025, down from $7.9 million in Q1 2024, which included pre-approval expenses for Emrosi [3] - Selling, general, and administrative expenses rose by $2.1 million to $10.6 million in Q1 2025, primarily due to activities related to Emrosi's launch [3] Product Launch and Market Position - Emrosi, an oral treatment for rosacea, had a strong launch with initial prescriptions filled in late March 2025 and was included in the updated National Rosacea Society Treatment Algorithms [2][10] - The Phase 3 clinical trial results for Emrosi were published in JAMA Dermatology, demonstrating statistical superiority over Oracea and placebo [2][10] - The company aims for sustainable positive EBITDA and profitability in 2025, viewing it as a transformational year [2] Corporate Developments - Journey Medical appointed Ramsey Alloush as Chief Operating Officer in April 2025 [10] - The company held a conference call on May 14, 2025, to discuss its financial results and strategic objectives [5][6]